In early 2021, a leading French hospital launched a pioneering study to evaluate omega-3 fatty acids' potential in preventing acute respiratory distress syndrome (ARDS), the most severe complication of SARS-CoV-2 infection.
Pierre Weill, an agricultural engineer and founder of the Bleu-Blanc-Cœur association in Combourtillé (Ille-et-Vilaine), promotes sustainable farming practices that respect land and animals. As reported by Ouest France on October 14, 2020, Bleu-Blanc-Cœur is collaborating with Rennes University Hospital and INSERM, France's National Institute of Health and Medical Research.
This partnership focuses on assessing omega-3s' effects on ARDS, the most serious form of COVID-19. Pierre Weill notes that scientific literature on omega-3s in enteral nutrition for ARDS patients dates back over a decade, with recent studies advocating fish oil supplementation for COVID-19 cases.
Omega-3s are essential polyunsaturated fatty acids found in fatty fish and plants like flaxseed, rapeseed, and walnuts. Yet, dietary intake often falls short. Research from 2017 highlights their role in enhancing brain cell connections, promoting smoother cognitive function and reducing aggression.
The Rennes University Hospital study, set for early 2021 after regulatory approval, will examine omega-3s' preventive potential against SARS-CoV-2. Gastroenterologist Ronan Thibault, head of the nutrition unit, emphasizes their proven benefits in artificial nutrition, including lower mortality, shorter hospital stays, and reduced ventilation time.
This trial uniquely tests whether omega-3s can mitigate inflammatory responses in high-risk COVID-19 patients—a first-of-its-kind investigation.
